




February 2019

Volume 24 Number 2
pp. 361–664



Cover Story

The lead story in this issue of Drug Discovery Today is by Dmitry M. Volochnyuk, Sergey V. Ryabukhin, Yuri Moroz, Olena Savych, Alexander Chuprina, Dragos Horvath, Yuliana Zabolotna, Alexandre Varnek, and Duncan B. Judd and is entitled: "Evolution of commercially available compounds for HTS." The authors describe how an industry of compound suppliers has grown to provide drug discovery with screening compounds: it is estimated that there are over 16 million compounds available from these sources. They review the chemical space covered by suppliers' compound libraries (SCL) in terms of compound chemophysical properties, novelty, diversity, and quality.

DRUG DISCOVERY TODAY

EDITORIAL

361 **Toward improving drug delivery research in Egypt: Cancer Nanotechnology Research Laboratory (CNRL) as a role model**

Ahmed O. Elzoghby and May S. Freag

PERSPECTIVE

FEATURE

364 **Trends in interorganizational transactions in personalized medicine development**

Tomohiro Makino, Shintaro Sengoku, Shuichi Ishida and Kota Kodama

371 **Impact of dosing schedule in animal experiments on compound progression decisions**

Chao Chen

377 **Accelerating pharmaceutical structure-guided drug design: a successful model**

Lisa J. Keefe and Vincent S. Stoll

382 **Lost medicines: a longer view of the pharmaceutical industry with the potential to reinvigorate discovery**

Michael S. Kinch, Grant A. Kinch and Rebekah H. Griesenauer

REVIEWS

FOUNDATION

390 **Evolution of commercially available compounds for HTS**

Dmitriy M. Volochnyuk, Sergey V. Ryabukhin, Yuri S. Moroz, Olena Savych, Alexander Chuprina, Dragos Horvath, Yuliana Zabolotna, Alexandre Varnek and Duncan B. Judd

KEYNOTE

403 **Interplay between hereditary and environmental factors to establish an in vitro disease model of keratoconus**

Subhadeep Roy, Saumya Yadav, Tanushree Dasgupta, Shikha Chawla, Radhika Tandon and Sourabh Ghosh

417 **Gut reaction: impact of systemic diseases on gastrointestinal physiology and drug absorption**

Grace B. Hatton, Christine M. Madla, Sarit C. Rabbie and Abdul W. Basit

428 **Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets**

Sven Günther, Paolo Fagone, Gaël Jalce, Atanas G. Atanasov, Christophe Guignabert and Ferdinando Nicoletti

440 **A review of non-invasive insulin delivery systems for diabetes therapy in clinical trials over the past decade**

Najma Easa, Raid G. Alany, Mark Carew and Anil Vangala

452 **Meeting the discovery challenge of drug-resistant infections: progress and focusing resources**

Gordon Dougan, Chris Dowson and John Overington